Inclinix partners with JSW for European enrolment support

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

Fangzhou Inc. at PHARMCHINA Showcases AI-Powered Healthcare

The 4th Annual "Internet + Pharma" Service Innovation Conference,...

The Evolution of Self-Care: Where Vitauthority Fits in the Wellness Era

Over the past few decades, the concept of self-care...

Piramal Pharma Expands Lexington Sterile Injectables Plant

Piramal Pharma has started work on the expansion of...

China Unveils Innovative Drugs Policy to Boost Development

The National Health Commission and China's National Healthcare Security...

Inclinix, a US-based contract research organisation (CRO) that provides customised solutions for patient enrolment to Phase I-IV clinical trials, has raised its profile in Eastern and Western Europe through a formal strategic partnership with JSW Life Sciences, a full-service CRO based in Austria and specialising in diseases of the central nervous system.

The partnership gives Inclinix offices in Graz, Austria and an expanded team that includes more than 100 enrolment professionals in Eastern and Western Europe. President and chief executive officer J. Tobin Geatz pointed to the company’s “significant growth†over the past year, which made it “important for us to identify a European partner that shares our philosophy and performance enrolment modelâ€.

Inclinix’s Clinical Enrollment Manager (CEM) programmes provide in-field support to investigative sites conducting clinical trials. The CEMs seek to identify suitable study candidates not only from within the sites’ practices but from the surrounding medical and patient communities as well. JSW’s preclinical research department focuses on drug development for neurodegenerative diseases, while its clinical research team handles anything from first-in-human Phase I trials through to post-marketing surveillance studies.

Latest stories

Related stories

Fangzhou Inc. at PHARMCHINA Showcases AI-Powered Healthcare

The 4th Annual "Internet + Pharma" Service Innovation Conference,...

The Evolution of Self-Care: Where Vitauthority Fits in the Wellness Era

Over the past few decades, the concept of self-care...

Piramal Pharma Expands Lexington Sterile Injectables Plant

Piramal Pharma has started work on the expansion of...

China Unveils Innovative Drugs Policy to Boost Development

The National Health Commission and China's National Healthcare Security...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back